Abdominal Aortic Aneurysm

作者：Jonathan Golledge, Juanita Muller, Alan Daugherty, Paul Edward Norman · 发表于：Arteriosclerosis Thrombosis and Vascular Biology · 年份：2006 · DOI：10.1161/01.atv.0000245819.32762.cb · 被引用次数：631 · 研究领域：Aortic aneurysm repair treatments、Aortic Disease and Treatment Approaches、Abdominal vascular conditions and treatments

Abdominal aortic aneurysm (AAA) affects approximately 5% of elderly men and is responsible for a significant number of deaths in Western Countries. At present surgery by open or endovascular means is the only widely used therapy for this condition. In this review we examine the risk factors, serum, and genetic associations of AAA. Epidemiology studies suggest that smoking cessation and control of cholesterol and blood pressure should reduce the number of patients developing AAA. Natural history studies suggest that smoking cessation should reduce the rate of progression of AAA. Clear level 1 evidence for drug treatments of AAA are presently lacking; however, animal and human in vitro studies suggest that medication targeted at reducing inflammation and proteolysis are most likely to be beneficial, with limited data to support the use of statins, Angiotensin II inhibitors, and macrolides. Work has commenced in understanding which patients, identified by clinical, serum, and genotype, are more at risk of AAA progression and thus should be selected out for aggressive treatment. Well designed large multicenter randomized controlled trials are required to examine the medical treatment of AAA.